biostudies-literatureUnknown7Humphries MPMale breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negScientific reports45293https://www.ebi.ac.uk/biostudies/studies/S-EPMC5368596biostudies-literatureCharacterisation of male breast cancer: a descriptive biomarker study from a large patient series.PMC5368596Hanby AMProvenzano EFulford LHumphries MPStephens MJones JLTitloye ANSpeirs VJordan LBKanthan RShousha SEllis IOCserni GDi Benedetto ALitwiniuk MMottolese MSundara Rajan SHonarpisheh HKulka JDent JShaaban AMfalseCharacterisation of male breast cancer: a descriptive biomarker study from a large patient series.Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity neg2017-01-01T00:00:00Z2017 Mar2025-04-04T18:45:23.566Z2019-03-27T02:39:41ZS-EPMC53685962835001110.1038/srep45293